Related Experiment Video
Updated: Aug 2, 2026
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
Published on: June 10, 2022
Biodistribution of lipid nanoparticle, eGFP mRNA and translated protein following subcutaneous administration in
Åsa Sandelius1, Humaira Naseer2, Johnny Lindqvist1
1Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceutical R&D, AstraZeneca, Pepparredsleden 1, Mölndal, SE 43183, Sweden.
Abstract:
Aim: Increased knowledge of biodistribution and pharmacokinetics of lipid nanoparticle (LNP)-encapsulated mRNA drug components may aid efficacy and safety evaluation.Methods: Mice were subcutaneously administrated LNP encapsulated enhanced green fluorescent protein mRNA and sampled up to 72 h after dosing. LNP, mRNA and translated protein were quantified by LC-MS, branched DNA and ELISA.Results: Highest levels of LNP and mRNA were detected in skin, followed by spleen, but also rapidly distributed to circulation. Translated protein showed high concentration in skin and spleen, but also in liver and kidney across 24 h where the LNP was cleared at 4 h.Conclusion: Subcutaneously dosing LNP encapsulated mRNA in mice resulted in a nonlinear relationship of LNP, mRNA and protein concentration across multiple tissues.
